Delving into the Latest Updates on Ceftriaxone Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Acantex, Ceftezole Sodium, Ceftriaxone

+ [26]

Target

PBPs

Action

inhibitors

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors

Therapeutic Areas

Infectious DiseasesNervous System DiseasesRespiratory Diseases+ [6]

Active Indication

Arthropathy associated with infectionInfection of bonePostoperative infection+ [23]

Inactive Indication

HIV InfectionsNeurosyphilis

Originator Organization

F. Hoffmann-La Roche Ltd.

Active Organization

Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.

Shanghai Bao Pharmaceutical Co. Ltd.

Shanghai Roche Pharmaceuticals Ltd.

+ [3]

Inactive Organization

Hoffmann-La Roche, Inc.

License Organization

Everest Medicines Ltd.

Roche Holding AGHasten Biopharmaceutical Co., Ltd.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (21 Dec 1984),

Bacterial Infections

RegulationOrphan Drug (European Union)

Login to view timeline

Structure/Sequence

Molecular FormulaC36H50N16Na4O21S6

InChIKeyHPYJOGROSRTMBB-MAODNAKNSA-N

CAS Registry104376-79-6

A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments for the Intensive Phase of Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

The goal of this clinical trial is to learn if a new combination antibiotic treatment (Arm D) works to treat a rare lung condition called mycobacterium abscessus pulmonary disease in people of any age and sex, when compared to the standard treatments. It will also learn about the safety of this new combination antibiotic treatment when compared to the standard treatments. The main questions it aims to answer are:
* How well does Arm D treat mycobacterium abscessus pulmonary disease?
* What side effects does Arm D cause when used to treat mycobacterium abscessus pulmonary disease? Researchers will compare Arm D to the current standard of care treatments to see if Arm D treats mycobacterium abscessus pulmonary disease better and if it will cause less side effects.
Participants will:
* Be screened and recruited to the FORMaT adaptive platform trial (NCT04310930)
* Be given Arm D for 4 weeks or standard of care treatments for 6 weeks.
* Be reviewed by the study doctors weekly for checkups and tests.
* Provide respiratory samples (sample coughed up from the chest), respond to quality-of-life questionnaires, have CT lung scans and blood tests.

Start Date01 Apr 2027

Sponsor / Collaborator

The University of Queensland

[+1]

NCT03895567

/ SuspendedPhase 1IIT

A Randomised Crossover Study of the Pharmacokinetics, Safety and Tolerability of Two Rectal Formulations of Ceftriaxone Compared to Parenteral Ceftriaxone, in Healthy Thai Adults.

Phase 1, three-way cross-over, randomised, open label comparison of intravenous versus two rectal dosage forms of ceftriaxone in 37 healthy Thai adults.
The following regimens will be evaluated in random order in all participants:
A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1-hard-shell gelatin capsule (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2-rectodispersible mannitol-based tablet (1 x 500mg)
Possible schedules: ABC, ACB, BAC, BCA, CAB, CBA. Each recipient will receive a single treatment dose of each of the three formulations in an order predetermined by a computer generated randomisation list. This will be a constrained randomization which ensures approximately balanced proportions for all six schedules (either 6 or 7 participants per schedule). There will be 7-28 days washout period between doses. The last follow up visit is 28 (+ 2) days after final dose. Participants lost to follow-up or unevaluable for any reason before completion of pharmacokinetic sampling after the final dose will be replaced at the discretion of the investigators with another participant of the same population, if either sample size or completeness of dataset is compromised.
This study is funded by the Medical Research Council. The grant reference number is MR/W021560/1

Start Date01 Dec 2026

Sponsor / Collaborator

University of Oxford

NCT07537413

/ Not yet recruitingPhase 4IIT

Pragmatic Randomized Trial Evaluating Dosage of Ceftriaxone for Community-Acquired Pneumonia Outside the Intensive Care Unit

Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.

Hypothesis: Among hospitalized patients outside of the intensive care unit with community-acquired pneumonia who are prescribed Ceftriaxone, a dosage of 1 gram daily will be associated with an equivalent rate of clinical cure and fewer adverse events than a dosage of 2 grams daily.

Start Date01 Sep 2026

Sponsor / Collaborator

University of Maryland Baltimore

100 Clinical Results associated with Ceftriaxone Sodium

Login to view more data

100 Translational Medicine associated with Ceftriaxone Sodium

Login to view more data

100 Patents (Medical) associated with Ceftriaxone Sodium

Login to view more data

25,053

Literatures (Medical) associated with Ceftriaxone Sodium

01 Jul 2026·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

The dual binding of pantoprazole mitigates ceftriaxone-mediated misfolding of human serum albumin

Article

Author: Ahmad, Basir ; Noor, Sakhaviya ; Parvez, Suhel ; Qureshi, Afnaan

Proton pump inhibitors (PPIs) like pantoprazole are often prescribed alongside antibiotics to prevent antibiotic-induced gastritis, ulcers, and microbiome disturbances. In this study, we provide the first evidence of pantoprazole's (PTP) distinct protective role in preventing ceftriaxone (CTX) induced structural alterations and aggregation of human serum albumin (HSA). We have found strong binding of pantoprazole at domain-I and domain-III, whereas ceftriaxone binds in domain-II of HSA. The ceftriaxone binding was found to disrupt the tertiary structure of the protein and induces the non-native β-structures without affecting the thermal stability of the protein. Moreover, it was found to promote the thermal-induced formation of protofibrils. However, the addition of pantoprazole in HSA-CTX complex efficiently restored the structural alterations and aggregation reaction. This study highlights a previously unrecognized protective role of PPIs, particularly pantoprazole, in preserving protein structure and aggregation caused by antibiotic overuse.

01 Jun 2026·Biofilm

Staphylococcal persistence and biofilm resistance in bone-anchored hearing systems: Clinical impact

Article

Author: Hoffman, Maria ; Hultcrantz, Malou ; Ganeyev, Marsel ; Trobos, Margarita ; Thomsen, Peter ; Johansson, Martin L ; Palmquist, Anders ; Morales-Laverde, Liliana

Persistent inflammation and infection, often linked to staphylococcal colonization, affect bone-anchored hearing system (BAHS) outcomes. Although antibiotics are often used to treat skin complications, the roles of biofilms and antimicrobial resistance (AMR) in clinical success remain unclear. This clinical prospective study characterized biofilm formation and antibiotic resistance in Staphylococcus spp. from BAHS patients, and examined associations with inflammation, pain, and hygiene. Adults eligible for BAHS were prospectively enrolled at a tertiary university hospital in Sweden during 2014-2015. Fifteen patients were followed clinically and microbiologically at surgery, 3- and 12- months. Abutment, peri-abutment exudate and soft-tissue samples were cultured. Fifty-seven Staphylococcus spp. isolates underwent biofilm phenotyping (Crystal Violet, Congo Red), antimicrobial susceptibility testing (minimum inhibitory concentration [MIC], minimum biofilm eradication concentration [MBEC]) and whole-genome sequencing (lineage, AMR and virulence genes). Clinical status was scored (Holgers, pain, debris). Individual patients harbored the same staphylococcal clone on abutment, exudate, and tissue for 12 months. S. aureus was more prevalent in patients with inflammation (Holgers score >0), S. epidermidis correlated with pain, and slime production was associated with debris accumulation. Overall, 56 % of isolates showed resistance to fusidic acid, and 11-34 % carried tetracycline resistance genes. S. epidermidis carried multidrug resistance genes (beta-lactams, tetracycline, sulfamethoxazole, fosfomycin), and resistance increased under biofilm conditions (MBEC > MIC). The ica operon was detected in all S. aureus and S. epidermidis ST7, ST297, ST749 and ST278. These findings indicate that staphylococci from BAHS exhibit persistent colonization, diverse clonal lineages, and high biofilm-associated AMR. Early microbial diagnostics and biofilm-targeted strategies, alongside cautious use of topical antibiotics, may improve outcomes.

01 Jun 2026·AMERICAN JOURNAL OF EMERGENCY MEDICINE

A rare case of lung hernia associated with rib fractures and tension pneumothorax post cardiopulmonary resuscitation

Article

Author: Raviraj, Abhiramee ; Lee, Yit Jian ; Tsao, Henry

Rib fractures are the most common injury after cardiopulmonary resuscitation (CPR) for non-traumatic cardiac arrest. Pneumothorax can evolve into tension pneumothorax with assisted ventilation leading to hypotension and cardiac arrest. Lung hernia post-CPR is rare but a potentially fatal complication. Here we describe a 67-year-old female who presented to the emergency department (ED) with acute infective asthma exacerbation. She received initial treatment of inhaled salbutamol and ipratropium bromide, oral prednisolone, supplemental oxygen, and intravenous ceftriaxone. Shortly after administration of ceftriaxone, she went into unexpected cardiac arrest. She had return of spontaneous circulation with cardiopulmonary resuscitation but remained unconscious. She was intubated but subsequent resuscitation was complicated by tension pneumothorax, bronchospasm resulting in dynamic hyperinflation, rib fractures, and lung hernia. The lung hernia was initially mistaken as subcutaneous emphysema on chest radiography. Despite epinephrine infusion, mechanical ventilation, and decompression tube thoracostomy, the patient suffered a second cardiac arrest and further resuscitation was ceased. The case demonstrates that lung hernia may be misinterpreted as subcutaneous emphysema secondary to tube thoracostomy on chest radiography. Early recognition for consideration of surgical intervention is essential especially in patients with incarcerated lung hernia and respiratory failure.

98

News (Medical) associated with Ceftriaxone Sodium

20 Apr 2026

·www.biospace.com

Fedora Pharmaceuticals Presentations at 2026 ESCMID Highlight Safety and Potent Bactericidal Activity of FPI-2119

Potent antibacterial activity against Gram-negative community and hospital-acquired infections highlighted across eight posters and two presentationS EDMONTON, Alberta , April 19, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. , a leader in the development of drugs to treat antibiotic-resistant infections, is presenting a full suite of preclinical findings from the company’s lead candidate, FPI-2119 at the European Society of Clinical Microbiology and Infectious Diseases Congress (ESCMID) in Munich, Germany. Presentations at ESCMID are authored by Fedora as well as collaborators at St. Jude Children’s Research Hospital, JMI Laboratories (Part of Element), Indiana University, and Pharmacology Discovery Services (a Eurofins Discovery Partner Lab). ESCMID presentations will highlight the candidate’s activity against some of the most difficult-to-treat Gram-negative infections, including respiratory tract infections, sexually transmitted infections, and high-mortality nosocomial infections. Many of these pathogens are in the high-priority category in the World Health Organization (WHO) Bacterial Priority Pathogens List (BPPL) due to the public health challenges they present and the limited treatment options available. “For decades, the medical community has relied on antibiotics to ensure the effective treatment of both hospitalized patients and those with community-acquired infections such as urinary tract infections (UTIs),” explained Karen Bush, Ph.D. , Indiana University professor emerita and member of the Fedora scientific advisory board. “Research into new antibacterial agents is very limited in spite of the fact that pathogens continue to evolve new resistance mechanisms. Every year increasing treatment failures occur to previously reliable antibacterial agents. This puts hospital patients and the greater community at serious risk of succumbing to infections that were once easily treatable. The data being presented at ESCMID show that FPI-2119 has the potential to become a valuable tool to fight today’s infectious diseases.” Fedora’s poster presentations at ESCMID highlight the following findings from preclinical studies of FPI-2119: Concentration-dependent bactericidal activity and low frequency of resistance against Pseudomonas aeruginosa (Poster 2568) Maintenance of activity against Escherichia coli strains carrying a broad range of potent β-lactamase encoding genes, confirming its stability in the presence of this resistance mechanism (Poster 2580) Activity against a collection of bacterial isolates, including resistant strains of Campylobacter , Salmonella , and Shigella , as well as Haemophilus influenzae and Moraxella catarrhalis , which are commonly associated with intestinal and respiratory tract infections (Poster 2581) Potency against all strains of N. gonorrhoeae including six that are resistant to penicillin, tetracycline, and ciprofloxacin, three of which exhibit reduced susceptibility to ceftriaxone (Poster 2583) No measurable cardiotoxicity and clean off-target safety profile (Poster 2599) Potency at comparable or lower concentrations than cefepime to treat multidrug-resistant strains of P. aeruginosa , E. coli , and Klebsiella pneumoniae (Poster 2601) Statistically significant and dose-dependent reductions in bacterial burden in bladder and kidney in a mouse model of complicated UTI (Poster 2643) Half-life and plasma concentrations predictive of BID (twice a day) or QD (once a day) dosing in humans (Poster 2801) “Our first pipeline candidate, nacubactam, is a β-lactamase inhibitor with the potential to restore bactericidal activity to β-lactam antibiotics,” stated Christopher Micetich , chief executive officer and founder of Fedora Pharmaceuticals. “FPI-2119, our second candidate, is a potent antibiotic with the potential to treat infections caused by pathogens that produce β-lactamases. Together, these candidates offer innovative strategies to address the urgent need to treat resistant infections.” About FPI-2119 FPI-2119, a first-in-kind derivative of the lactivicin class, is in development for the treatment of Gram-negative infections. As a non-β-lactam antibiotic, FPI-2119 lacks the classical ring structure that defines that class. It is therefore not expected to be susceptible to β-lactamases, a resistance mechanism bacteria have developed to thwart β-lactam antibiotics such as cefepime. FPI-2119 has demonstrated a broad spectrum of activity against multiple Gram-negative pathogens including Pseudomonas aeruginosa , Acinetobacter baumannii , Enterobacterales, and other clinically significant pathogens. Target indications include complicated hospital-acquired and ventilator-associated bacterial pneumonia (cHABP/cVABP), complicated urinary tract infections (cUTI), and complicated intra-abdominal infections (cIAI). About Fedora Pharmaceuticals Fedora Pharmaceuticals Inc. is an innovative biotech founded in 2011 and headquartered in Edmonton, Alberta, Canada. The company is dedicated to discovering and developing novel antimicrobial drugs to tackle antibiotic resistance (AMR). With a strong pipeline and expert scientific team, Fedora’s mission is to deliver solutions that impact global health. Fedora’s most advanced candidate is nacubactam, a Phase 3-ready β-lactamase inhibitor being advanced with partner, Meiji Seika. Fedora holds key US rights to nacubactam. Fedora is seeking development partners for nacubactam in the US. For more information, please visit . About St. Jude Children's Research Hospital St. Jude Children’s Research Hospital is leading the way the world understands, treats, and cures childhood catastrophic diseases. From cancer to life-threatening blood disorders, neurological conditions, and infectious diseases, St. Jude is dedicated to advancing cures and means of prevention through groundbreaking research and compassionate care. Through global collaborations and innovative science, St. Jude is working to ensure that every child, everywhere, has the best chance at a healthy future. To learn more, visit stjude.org , read St. Jude Progress , a digital magazine, or contact St. Jude at media@stjude.org. CONTACT: Media and Investors: info@fedorapharma.com

Phase 3Qualified Infectious Disease Product

24 Feb 2026

·www.biospace.com

Roche Seeks Antibiotic Partner as Rising Manufacturing Costs Drive Supply Rethink

iStock, olli0815 The company plans to divest a drug it has made for 40 years, citing increasing production costs and falling prices. Roche has started looking for a partner to handle production and supply of Rocephin after concluding it is becoming “increasingly unsustainable” to make the antibiotic in Switzerland. Rocephin is Roche’s brand name for ceftriaxone, a long-acting, broad spectrum cephalosporin antibiotic. Since ceftriaxone was approved in the 1980s, physicians have used the injectable antibiotic to treat conditions such as sepsis and meningitis in children and adults. The antibiotic is on the World Health Organization’s list of essential medicines. Roche serves the market from its production site in Kaiseraugst, Switzerland. Yet after manufacturing the antibiotic for 40 years, Roche is now seeking a production partner. AWP Financial News first reported the development, which a Roche spokesperson confirmed to BioSpace via email. “The decision was made because production of Rocephin in Switzerland is becoming increasingly unsustainable due to the rising cost of manufacturing, the reduction in prices that governments are willing to pay for Rocephin and the widespread use of generics in many countries around the world,” the spokesperson said. Roche has spoken with the European Commission’s Health Emergency Response Authority and the Swiss Federal Office of Public Health over the past two years to try to find ways to address the challenges, the spokesperson said. However, the parties were unable to agree on a way to secure sustainable production at the site, leading Roche to commit to divesting Rocephin. The company plans to start the process this year, and the earliest it could be completed is the end of the decade, the spokesperson said. The company has informed the European Union and Swiss authorities about its decision. Roche’s move to divest Rocephin comes amid a push by EU authorities to encourage drug production in the region. Supply disruptions during the pandemic, recent trade tensions with the U.S. and pressure to make the EU more competitive have combined to drive lawmakers to propose changes to prevent drug shortages and lessen reliance on imports. Under the Critical Medicines Act, for example, countries could favor suppliers that manufacture a significant portion of certain products in the EU. The legislation, which has entered the final phase of negotiations between EU bodies, is intended to move the EU away from procurement policies that focus primarily on price. Insights New UK/EU Rules and AI Adoption Define CRO Priorities for 2026 With new UK clinical trial rules landing in 2026, the EU Biotech Act on the horizon and China and Australia gaining ground, CROs are zeroing in on study timelines, AI/ML and data privacy as the industry’s next pressure points. December 3, 2025 · 4 min read · Jennifer Smith-Parker Read more

Drug Approval

20 Feb 2026

·www.fiercepharma.com

Roche looks to divest its former blockbuster antibiotic amid EU generics woes

Near its headquarters in Basel, Switzerland, Roche is seeking to divest a manufacturing facility and find a partner to produce the former blockbuster antibiotic Rocephin. After manufacturing the antibiotic Rocephin for four decades—and developing it into one of the company’s first blockbuster medicines—Roche is looking to divest the treatment and its production facility near its headquarters in Basel, Switzerland.Roche is seeking a partner to take over the plant and continue production of the drug, also known as ceftriaxone sodium, which has faced generic competition over the last two decades. Local outlet AWP Financial News reported the effort earlier this week. “The decision was made because production of Rocephin in Switzerland is becoming increasingly unsustainable due to the rising cost of manufacturing, the reduction in prices that governments are willing to pay for Rocephin and the widespread use of generics in many countries around the world,” the company wrote in a statement to Fierce Pharma Manufacturing. Roche added that its divestment effort comes after unsuccessful discussions for two years with the European Commission’s Health Emergency Response Authority and Switzerland’s Bundesamt für Gesundheit “to secure sustainable production at the site.”The company added that the divestment of the plant, which houses roughly 100 employees, will “not be complete before the end of the decade.” Roche also pointed out that it is not abandoning the antibiotics market nor diminishing its presence in Switzerland. Last year, the company revealed plans to conduct a phase 3 trial of its novel antibiotic zosurabalpin for carbapenem-resistant acinetobacter baumannii.“We stand by our strong commitment to developing new antibiotics and tackling antimicrobial resistance (AMR), as well as to our sites in Switzerland,” the company wrote. The decision comes as European drugmakers are fleeing the market because regulatory and environmental pressures have made production of generics less attractive. The departures have left the EU with a sourcing problem as it already relies heavily on products from China. Last month, the bloc passed the Critical Medicines Act to increase competitiveness and tackle shortages.The FDA approved Rocephin in 1984 as a treatment for severe bacterial infections including meningitis, sepsis and pneumonia. Roche, which billed as Rocephin as the “No. 1 hospital product” in the U.S. market, lost its patent protection for the injected antibiotic all the way back in 2005.

Drug ApprovalAcquisitionPhase 3

100 Deals associated with Ceftriaxone Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00924	Ceftriaxone Sodium	J01DD04	DB01212

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Arthropathy associated with infection	Australia	Juno Pharmaceuticals Pty Ltd.	28 Jan 2003
Infection of bone	Australia	Juno Pharmaceuticals Pty Ltd.	28 Jan 2003
Postoperative infection	Australia	Juno Pharmaceuticals Pty Ltd.	28 Jan 2003
Skin and skin structure infections	Australia	Juno Pharmaceuticals Pty Ltd.	28 Jan 2003
Genitourinary tract infection	China	Shanghai Roche Pharmaceuticals Ltd.	01 Jan 1998
Lyme Disease	China	Shanghai Roche Pharmaceuticals Ltd.	01 Jan 1998
Reproductive Tract Infections	China	Shanghai Roche Pharmaceuticals Ltd.	01 Jan 1998
Respiratory Tract Infections	China	Shanghai Roche Pharmaceuticals Ltd.	01 Jan 1998
Wound Infection	China	Shanghai Roche Pharmaceuticals Ltd.	01 Jan 1998
Biliary tract infection	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Bone and joint infections	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Gonorrhea	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Infectious Diseases	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Intraabdominal Infections	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Lower Respiratory Tract Infections	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Meningitis	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Pelvic Infection	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Sepsis	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Skin structures and soft tissue infections	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991
Urinary Tract Infections	China	Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.	01 Jan 1991

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Infection of ear	Clinical	China	Shanghai Bao Pharmaceutical Co. Ltd.	08 Aug 2025
Nasal infection	Clinical	China	Shanghai Bao Pharmaceutical Co. Ltd.	08 Aug 2025
Peritonitis	Clinical	China	Shanghai Bao Pharmaceutical Co. Ltd.	08 Aug 2025
Pharyngitis	Clinical	China	Shanghai Bao Pharmaceutical Co. Ltd.	08 Aug 2025
Pneumonia	Clinical	China	Shanghai Bao Pharmaceutical Co. Ltd.	08 Aug 2025
HIV Infections	Clinical	United States	Hoffmann-La Roche, Inc.	31 Aug 2001
Neurosyphilis	Clinical	United States	Hoffmann-La Roche, Inc.	31 Aug 2001

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAAAI2026	Not Applicable	-	86	Cefazolin	wzyfbvntnx(kbkmpmimvp) = glgahdcyvm xzmtslagrc (hxqtfefpnm ) View more	Positive	27 Feb 2026
NCT05980871 (CTgov)	Phase 4	Syphilis	109	CRO+Doxy (CRO/Doxy)	qfawuwepia = zmevrtbnqa hvhhbejemq (tdaprvfjmc, odnkgqhshh - dqgrohzedn) View more	-	25 Feb 2026
				BPG+Doxy (BPG/Doxy)	qfawuwepia = dbowtsaicy hvhhbejemq (tdaprvfjmc, ayarsaxbns - biinpmhsst) View more
EURETINA2025	Not Applicable	Uveitis	25	Intravenous Ceftriaxone + Oral Corticosteroids	sxcinnffwr(byjyqykdec) = awlnbjbxpw ynltfauzit (enahzvqgnq, 0.07) View more	Positive	04 Sep 2025
Literature Manual	Phase 2/3	Whipple Disease	64	oral doxycycline +hydroxychloroquine	knbyjzfjqs(wvehslbhxn) = zmvumrsylw exlcbjxxmp (lkyisjpmej ) View more	Non-inferior	17 Feb 2025
				intravenous ceftriaxone+oral trimethoprim-sulfamethoxazole	knbyjzfjqs(wvehslbhxn) = ymnxlruloo exlcbjxxmp (lkyisjpmej ) View more
NCT05027516 (ResistAZM, CTgov)	Phase 4	Gonorrhea	42	Rocephin (Rocephine®)	pvljjezhug(spdmxexekt) = nimdqwepdi ewoscaddab (bzdghoocns, heaxkrnpxz - wmgzhojozn) View more	-	02 Aug 2024
				Azithromycin+Rocephin (Rocephine® + Azithromycin)	dsoxeyaptc = zjfxmcbtwg befakqzpbt (oldykcufdw, fhitexsije - axvirtcptq) View more
NCT02265406 (PROPHY-VAP, Pubmed \| Lancet Respir Med) Manual	Phase 3	Pneumonia, Ventilator-Associated	319	Ceftriaxone 2 g	lpskipnqld(rifoqfpicd) = cuavejbkuu agbmxuoswt (yuglcmfims )	Positive	19 Jan 2024
				Placebo	lpskipnqld(rifoqfpicd) = bxarwypxwz agbmxuoswt (yuglcmfims )
NCT04218695 (Pubmed) Manual	Phase 4	Infectious Diseases	30	ceftriaxone	kxzwfhjzwc(gkbscuwjfq) = There were no observed statistically significant differences between groups in incidence of infection, mortality, length of stay, or key laboratory parameters, including C-reactive protein and procalcitonin. xuweubsllr (cklectxqum )	Negative	01 Jan 2024
				Placebo
NCT05149287 (PROPER, CTgov)	Phase 2	Meniscus disorder \| Inflammation \| Cartilage Injury ... View more	5	Ceftriaxone (Experimental)	mdgupuosqt(jlegrsksak) = pqpedeegdl tnlnmoxqdw (rklbvvhpvp, 1.11) View more	-	05 Sep 2023
				Placebo (Placebo)	mdgupuosqt(jlegrsksak) = nvfkjtylyb tnlnmoxqdw (rklbvvhpvp, 2.97) View more
NCT01265173 (Pubmed \| Am J Gastroenterol)	Not Applicable	Spontaneous bacterial peritonitis First line	261	Cefotaxime	gooulxqrsg(wduhcpcryt) = tplymasyfb nsgdjiohbp (xflnmaymfs )	-	02 Jan 2023
				Ceftriaxone	gooulxqrsg(wduhcpcryt) = ojzdjnlqpr nsgdjiohbp (xflnmaymfs )
NCT04218695 (CTgov)	Phase 4	Fibrosis \| Liver Cirrhosis	32	Ceftriaxone (Treatment)	lnlufolwvg = dakddfkdep ygmfiowbzc (nslkgqacfd, alplzbhpeg - yhzpjfcplh) View more	-	31 Aug 2022
				Normal saline (Placebo)	lnlufolwvg = khrlszozzz ygmfiowbzc (nslkgqacfd, fupjflfwlp - jvjetlnuyy) View more